The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27003516 |
78 |
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold. |
The University of Kansas |
26086931 |
38 |
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. |
Shandong University |
25901531 |
211 |
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. |
Sloan-Kettering Institute For Cancer Research |
25027801 |
8 |
Development of radamide analogs as Grp94 inhibitors. |
The University of Kansas |
24673104 |
185 |
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease. |
Vertex Pharmaceuticals |
24332488 |
11 |
Correlation between chemotype-dependent binding conformations of HSP90a/ß and isoform selectivity-Implications for the structure-based design of HSP90a/ß selective inhibitors for treating neurodegenerative diseases. |
Vertex Pharmaceuticals |
22938030 |
22 |
EC144 is a potent inhibitor of the heat shock protein 90. |
Biogen Idec |
20055425 |
29 |
Heat shock protein 90: inhibitors in clinical trials. |
Biogen Idec |
31839539 |
60 |
Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1. |
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif) |
31663736 |
15 |
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. |
China Pharmaceutical University |
30351001 |
16 |
Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. |
China Pharmaceutical University |